China's Zeesan Biotech Developing Portfolio of Melt Curve MDx Assays after SFDA Approves TB Tests | GenomeWeb

This article has been updated from a previous version to clarify information regarding the development and commercialization of Zeesan Biotech's assays.

The Chinese State Food and Drug Administration recently approved a pair of tuberculosis drug-resistance assays developed by Xiamen-based molecular diagnostics firm Zeesan Biotech, PCR Insider has learned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.